Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Commentary

COVID-19 Vaccination, Peltzman Effect and Possible Increase in Highrisk Behaviors: A Growing Concern Related to Risk Compensation and Reduced Compliance to Public Health Protective Measures after Vaccines Rollout

Author(s): Shahab Falahi, Jasem Mohamadi, Hojjat Sayyadi, Iraj Pakzad, Ayoub Rashidi, Razi Naserifar, Jahangir Abdi and Azra Kenarkoohi*

Volume 22, Issue 8, 2022

Published on: 10 August, 2022

Article ID: e190422203797 Pages: 5

DOI: 10.2174/1871526522666220419133849

Price: $65

Abstract

The world is still faced with widespread dissemination and many unanswered questions related to Coronavirus disease (COVID-19). Several candidate vaccines have been introduced against COVID-19, mostly requiring the injection of two doses and some with nearly 90-95% efficacy. All strategies against the spread of infection have focused on breaking the chain of virus transmission through protective public health measures and mass vaccination. The current situation emphasizes the global need for carefully designed policies to maximize vaccine access and uptake. The risk compensation theory (Peltzman Effect) states that the decrease in perceived risk through access to preventive measures may lead to increasing frequency of risky behaviors. The current pandemic has exposed people to the sense of risk compensation and behavior change in response to the perceived risk. Risk compensation phenomenon may significantly reverse the benefits of COVID-19 vaccination, especially if the vaccine is not sufficiently effective in real life or among high-risk populations. Recognition and awareness of Peltzman risk compensation are of high importance in counteracting and neutralizing the false complacency of the community, which also lends more weight to public health efforts. The public health messages and practices should be clearly expressed, straightforward, reliable and applicable. It is important to encourage mass vaccination of the population, and other NPIs must be re-established and implemented to ensure education to live with COVID-19 in parallel with daily activities and job tasks.

Keywords: COVID-19, pandemic, vaccination, risk compensation, Peltzman effect, risk homeostasis, risk management, highrisk behaviors, public health measures, non-pharmaceutical interventions, vaccines rollout.

[1]
Falahi S, Kenarkoohi A. Sex and gender differences in the outcome of patients with COVID‐19. J Med Virol 2021; 93(1): 151-2.
[PMID: 32603509]
[2]
Abdoli A, Taghipour A, Pirestani M, et al. Infections, inflammation, and risk of neuropsychiatric disorders: The neglected role of “co-infection”. Heliyon 2020; 6(12): e05645.
[http://dx.doi.org/10.1016/j.heliyon.2020.e05645] [PMID: 33319101]
[3]
Abdoli A, Falahi S, Kenarkoohi A. COVID-19-associated opportunistic infections: A snapshot on the current reports. Clin Exp Med 2021; 1-20.
[http://dx.doi.org/10.1007/s10238-021-00751-7] [PMID: 34424451]
[4]
Kenarkoohi A, Falahi S, Ghelijie F, Mirzaei A. Seroprevalence of hepatitis E virus infection among pregnant women in Ilam, west of Iran. Infect Disord Drug Targets 2021; 21(5): e270421187571.
[PMID: 33155920]
[5]
Falahi S, Bastani E, Pakzad I, Rashidi A, Abdoli A, Kenarkoohi A. Environmental surface contamination with SARS-CoV-2: Toilets as the most contaminated surfaces in COVID-19 referral hospital. Hosp Top 2021; 1-8.
[http://dx.doi.org/10.1080/00185868.2021.1969870] [PMID: 34445942]
[6]
Falahi S, Kenarkoohi A. COVID-19 reinfection: Prolonged shedding or true reinfection? New Microbes New Infect 2020; 38: 100812.
[http://dx.doi.org/10.1016/j.nmni.2020.100812] [PMID: 33200033]
[7]
Saberian P, Falahi S, Baratloo A, et al. Changes in COVID-19 IgM and IgG antibodies in emergency medical technicians (EMTs). Am J Emerg Med 2021; 52: 59-63.
[http://dx.doi.org/10.1016/j.ajem.2021.11.019] [PMID: 34864629]
[8]
Paltiel AD, Zheng A, Schwartz JL. Speed versus efficacy: quantifying potential tradeoffs in COVID-19 vaccine deployment. Ann Intern Med 2021; 174(4): 568-70.
[http://dx.doi.org/10.7326/M20-7866] [PMID: 33395345]
[9]
Ioannidis JPA. Benefit of COVID-19 vaccination accounting for potential risk compensation. NPJ Vaccines 2021; 6(1): 99.
[PMID: 34381059]
[10]
Jara A, Undurraga EA, González C, et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N Engl J Med 2021; 385(10): 875-84.
[http://dx.doi.org/10.1056/NEJMoa2107715] [PMID: 34233097]
[11]
Andrews N, Gower C, Stowe J, et al. Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England. medRxiv 2021.
[http://dx.doi.org/10.1101/2021.03.01.21252652]
[12]
Abdoli A, Falahi S, Kenarkoohi A. Uninfected but not unaffected: The COVID-19 stress could worsen the outcome of underlying diseases. 2021; 15(1)
[13]
Abdoli A, Falahi S, Kenarkoohi A, Shams M, Mir H, Jahromi MAM. The COVID-19 pandemic, psychological stress during pregnancy, and risk of neurodevelopmental disorders in offspring: A neglected consequence. J Psychosom Obstet Gynaecol 2020; 41(3): 247-8.
[http://dx.doi.org/10.1080/0167482X.2020.1761321] [PMID: 32380881]
[14]
Xiao K, Hou F, Huang X, Li B, Qian ZR, Xie L. Mesenchymal stem cells: Current clinical progress in ARDS and COVID-19. Stem Cell Res Ther 2020; 11(1): 305.
[http://dx.doi.org/10.1186/s13287-020-01804-6] [PMID: 32698898]
[15]
Kenarkoohi A, Bamdad T, Soleimani M, Soleimanjahi H, Fallah A, Falahi S. HSV-TK Expressing mesenchymal stem cells exert inhibitory effect on cervical cancer model. Int J Mol Cell Med 2020; 9(2): 146-54.
[PMID: 32934952]
[16]
Mohamed AA, Mohamad N, Mohamoud S, et al. SARS-CoV-2: The path of prevention and control. Infect Disord Drug Targets 2021; 21(3): 358-62.
[PMID: 32433010]
[17]
Abd-Elsalam S, Soliman S, Esmail ES, et al. Do zinc supplements enhance the clinical efficacy of hydroxychloroquine?: A randomized, multicenter trial. Biol Trace Elem Res 2020; 1-5.
[PMID: 33247380]
[18]
Abd-Elsalam S, Noor RA, Badvvi R, et al. Clinical-study evaluatinig the eficacy of ivermectin in COVID‐19 treatment a randomized controled study. J Med Virol 2021; 93(10): 5833-8.
[PMID: 34076901]
[19]
El-Bendary M, Abd-Elsalam S, Elbaz T, et al. Efficacy of combined sofosbuvir and daclatasvir in the treatment of COVID-19 patients with pneumonia: A multicenter Egyptian study. Expert Rev Anti Infect Ther 2022; 20(2): 291-5.
[http://dx.doi.org/10.1080/14787210.2021.1950532] [PMID: 34225541]
[20]
Abd-Elsalam S, Ahmed OA, Mansour NO, et al. Remdesivir efficacy in COVID-19 treatment: A randomized controlled trial. Am J Trop Med Hyg 2021; 106(3): 886-90.
[http://dx.doi.org/10.4269/ajtmh.21-0606] [PMID: 34649223]
[21]
Abd-Elsalam S, Noor RA, Badawi R, et al. Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled study. J Med Virol 2021; 93(10): 5833-8.
[http://dx.doi.org/10.1002/jmv.27122] [PMID: 34076901]
[22]
Organization WH. Advice on the use of masks in the context of COVID-19: Interim guidance, 5 June 2020. World Health Organization 2020.
[23]
Lazzarino AI, Steptoe A, Hamer M, Michie S. COVID-19: Important potential side effects of wearing face masks that we should bear in mind. BMJ 2020; 369: m2003.
[http://dx.doi.org/10.1136/bmj.m2003] [PMID: 32439689]
[24]
Mantzari E, Rubin GJ, Marteau TM. Is risk compensation threatening public health in the covid-19 pandemic? BMJ 2020; 370: m2913.
[PMID: 32713835]
[25]
Rubin GJ, Amlôt R, Page L, Wessely S. Public perceptions, anxiety, and behaviour change in relation to the swine flu outbreak: Cross sectional telephone survey. BMJ 2009; 339: b2651.
[http://dx.doi.org/10.1136/bmj.b2651] [PMID: 19574308]
[26]
Wright L, Fancourt D. Do predictors of adherence to pandemic guidelines change over time? A panel study of 22,000 UK adults during the COVID-19 pandemic. Prev Med 2021; 153: 106713.
[http://dx.doi.org/10.1016/j.ypmed.2021.106713] [PMID: 34242662]
[27]
Reiber C, Shattuck EC, Fiore S, Alperin P, Davis V, Moore J. Change in human social behavior in response to a common vaccine. Ann Epidemiol 2010; 20(10): 729-33.
[http://dx.doi.org/10.1016/j.annepidem.2010.06.014] [PMID: 20816312]
[28]
Trogen B, Caplan A. Risk compensation and COVID-19 vaccines. American College of Physicians 2021.
[http://dx.doi.org/10.7326/M20-8251]
[29]
Iyengar KP, Ish P, Botchu R, Jain VK, Vaishya R. Influence of the Peltzman effect on the recurrent COVID-19 waves in Europe. Postgrad Med J 2022; 98(2): e110-1.
[http://dx.doi.org/10.1136/postgradmedj-2021-140234] [PMID: 33927062]
[30]
Marlow LA, Forster AS, Wardle J, Waller J. Mothers’ and adolescents’ beliefs about risk compensation following HPV vaccination. J Adolesc Health 2009; 44(5): 446-51.
[http://dx.doi.org/10.1016/j.jadohealth.2008.09.011] [PMID: 19380091]
[31]
Gheysarzadeh A, Sadeghifard N, Safari M, et al. Report of five nurses infected with severe acute respiratory syndrome coronavirus 2 during patient care: Case series. Elsevier 2020; 36: p. 100694.
[http://dx.doi.org/10.1016/j.nmni.2020.100694]
[32]
Sadeghifar J, Jalilian H, Momeni K, et al. Outcome evaluation of COVID-19 infected patients by disease symptoms: A cross-sectional study in Ilam province, Iran. BMC Infect Dis 2021; 21(1): 903.
[http://dx.doi.org/10.1186/s12879-021-06613-7] [PMID: 34479500]
[33]
Desrichard O, Moussaoui L, Ofosu N. Do vaccinated people reduce their precautionary behaviours? A Test on a British Cohort 2021. Res Square 2021.
[http://dx.doi.org/10.21203/rs.3.rs-796025/v1]
[34]
Lei H, Xu M, Wang X, et al. Nonpharmaceutical interventions used to control COVID-19 reduced seasonal influenza transmission in China. J Infect Dis 2020; 222(11): 1780-3.
[http://dx.doi.org/10.1093/infdis/jiaa570] [PMID: 32898256]
[35]
Ma F, Zhong S, Gao J, Bian L, Eds. Influenza-like symptom prediction by analyzing self-reported health status and human mobility behaviors. Proceedings of the 10th ACM international conference on bioinformatics, computational biology and health informatics 2019. 233-42.
[http://dx.doi.org/10.1145/3307339.3342141]
[36]
Subramanian SV, Kumar A. Increases in COVID-19 are unrelated to levels of vaccination across 68 countries and 2947 counties in the United States. Eur J Epidemiol 2021; 36(12): 1237-40.
[http://dx.doi.org/10.1007/s10654-021-00808-7] [PMID: 34591202]
[37]
Thomas SJ, Moreira ED, Kitchin N, et al. Six month safety and] efficacy of the BNT162b2 mRNA COVID-19 vaccine. MedRxiv 2021.
[http://dx.doi.org/10.1101/2021.07.28.21261159]
[38]
Thomas SJ, Moreira ED Jr, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med 2021; NEJMoa2110345.
[39]
Gazit S, Shlezinger R, Perez G, et al. Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections. MedRxiv 2021.
[http://dx.doi.org/10.1101/2021.08.24.21262415]
[40]
Canaday DH, Oyebanji O, Keresztesy D, et al. Significant reduction in humoral Immunity among healthcare workers and nursing home residents 6 months AFTER COVID-19 BNT162b2 mRNA vaccination. MedRxiv 2021.
[http://dx.doi.org/10.1101/2021.08.15.21262067]
[41]
McMorrow M. Co-lead, Vaccine Effectiveness Team Representing EPI Task Force.. Improving communications around vaccine breakthrough and vaccine effectiveness EPI Task Force. Centres for Disease Control and Prevention. 2021. Available from: https://context-cdn.washingtonpost.com/notes/prod/default/documents/8a726408-07bd-46bd-a945-3af0ae2f3c37/note/57c98604-3b54-44f0-8b44-b148d8f75165
[42]
Kenar Koohi A, Ravanshad M, Rasouli M, Falahi S, Baghban A. Phylogenetic analysis of torque teno virus in hepatitis C virus infected patients in Shiraz. Hepat Mon 2012; 12(7): 437-41.
[http://dx.doi.org/10.5812/hepatmon.6133] [PMID: 23008723]
[43]
Mirrnejad R, Fallahi S, Kiani J, et al. Epidemic assessment of bacterial agents in osteomyelitis and their antibiotic resistance pattern determination. J Biol Sci 2008; 8(2): 478-81.
[http://dx.doi.org/10.3923/jbs.2008.478.481]
[44]
Ravanshad M, Sabahi F, Falahi S. Prediction of hepatitis B virus lamivudine resistance based on YMDD sequence data using an artificial neural network model. Hepat Mon 11(2): 108-13.

Rights & Permissions Print Cite
Article Metrics
4
© 2024 Bentham Science Publishers | Privacy Policy